Overview of Dr. Segal
Dr. Neil Segal is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of the Witwatersrand and has been in practice 21 years. Dr. Segal accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 90 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005
University of the WitwatersrandClass of 1996
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2007 - 2025
NC State Medical License 2020 - 2022
Clinical Trials
- Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer Start of enrollment: 2009 Jun 01
- Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2010 Dec 01
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 537 citationsClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerRona Yaeger, Walid K. Chatila, Marla Lipsyc, Jaclyn F. Hechtman, Andrea Cercek
Cancer Cell. 2018-01-08 - 297 citationsOrgan Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.Julio Garcia-Aguilar, Sujata Patil, Marc J Gollub, Jin K Kim, Jonathan B Yuval
Journal of Clinical Oncology. 2022-08-10 - 42 citationsLong-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.Floris S Verheij, Dana M Omer, Hannah Williams, Sabrina T Lin, Li-Xuan Qin
Journal of Clinical Oncology. 2024-02-10
Lectures
- First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Immune Therapy: Why Don't We Have the KEY for VICTORy?2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
ASCO21 Preview - Equity: Every Patient. Every Day. EverywhereMay 27th, 2021
INNATE PHARMA : Data from Phase I of Monalizumab and Durvalumab in MSS-CRC at ASCO 2018September 12th, 2018
Atezolizumab and Cobimetinib Regimen Shows Activity in CRCJune 15th, 2016- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
